Robaxacet

Quick links to important sections

Robaxacet

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Robaxacet

Quick Facts

Property Description
Active Ingredients Acetaminophen, Methocarbamol
Form Oral Solid Dosage (Caplet or Tablet)
Pharmacological Class Analgesic, Skeletal Muscle Relaxant
Common Use Relief of pain accompanied by muscle spasm
Origin Synthetic, Fixed-Dose Combination (FDC)

What Type of Medicine is Robaxacet?

Robaxacet is a fixed-dose combination (FDC) pharmaceutical product that is often available as an over-the-counter (OTC) medicine in several jurisdictions. It is delivered as an oral solid dosage form (caplet or tablet) and belongs to two distinct pharmacological classes: an analgesic and a skeletal muscle relaxant. This dual classification is the defining feature of the product, offering a comprehensive approach to managing acute discomfort where pain is complicated by muscle tightness. Methocarbamol, one of the active ingredients, is clinically recognized as a centrally-acting muscle relaxant that achieves its effect via the central nervous system, distinguishing it from agents that act directly on muscle tissue.

Composition: Acetaminophen and Methocarbamol

The product's identity is defined by its two primary active chemical substances: Acetaminophen and Methocarbamol. Acetaminophen is a non-opioid pain reducer supported by decades of clinical use for its reliable ability to increase the body's pain threshold. Methocarbamol is the component that addresses muscle tension, working centrally to suppress the nerve reflexes that cause excessive muscle spasms and rigidity. The combination is manufactured as a synthetic FDC, ensuring the consistent and simultaneous delivery of both therapeutic actions required for general relief.

General Purpose of this Dual-Action Relief

The primary general purpose of this combination product is the simultaneous relief of pain and associated muscle spasm—a unique positioning that targets two symptoms with one medicine. This formulation is clinically recognized for providing relief that addresses the cycle of discomfort where muscle tension often intensifies the perception of pain, and vice versa. The co-administration of an analgesic with a centrally-acting muscle relaxant aims to lessen the overall symptomatic burden by reducing involuntary muscle tightness while concurrently mitigating the accompanying pain sensation.

What side effects are possible with Robaxacet?

Possible Side Effects and Safety Information

Official regulatory documents describe the safety profile of Robaxacet based on the known risks of its two active components, Methocarbamol and Acetaminophen. The adverse reactions are classified across several physiological systems and are generally listed without specific common/uncommon frequency tiers, reflecting data gathered from clinical experience and post-marketing reports.

Systemic and Neurological Effects

The most commonly encountered effects listed in the regulatory profile are related to the Nervous System and involve symptoms such as drowsiness, dizziness, or headache. These effects may impair the mental and/or physical abilities required for performing hazardous tasks, such as driving or operating machinery. Other documented neurological effects include amnesia, confusion, blurred vision, and seizures.

Adverse reactions may also affect the Cardiovascular System (e.g., hypotension, syncope), the Digestive System (e.g., nausea, vomiting, jaundice), and the Hemic and Lymphatic System (e.g., leukopenia). Allergic reactions involving the Immune System and Skin (e.g., rash, pruritus, anaphylactic reaction) are also documented.

Serious Adverse Reactions and Population Constraints

Serious adverse reactions include life-threatening events such as anaphylactic reaction, syncope, and severe skin reactions. A critical safety warning associated with the Acetaminophen component is the risk of severe liver damage, including acute liver failure, especially when the maximum daily dosage is exceeded.

Safety constraints are documented for specific populations. The medicine's safety and effectiveness for pediatric patients under the age of 16 have not been established. Use during pregnancy is not considered established for safety, and there are reports of congenital abnormalities. Patients with hepatic or renal impairment must also be considered, as reduced clearance of Methocarbamol is documented and severe liver issues are a key constraint for Acetaminophen.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Robaxacet overdose addresses the dual toxicological risks posed by its two active ingredients: acetaminophen and methocarbamol. Overdose is classified as a life-threatening medical emergency.

Overdose may initially present with non-specific signs such as nausea, vomiting, sweating (diaphoresis), and abdominal pain, which can progress to severe central nervous system (CNS) depression, somnolence, and profound dizziness.

Severe Outcomes and Risks

Documented severe outcomes include acute hepatic necrosis and subsequent hepatic failure from the acetaminophen component, alongside the risk of seizures and coma from the muscle relaxant component. Patients with pre-existing hepatic impairment or chronic alcohol use are noted in official labeling to be at increased risk for severe hepatotoxicity.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose, regardless of whether symptoms are apparent, due to the critical nature of delayed liver damage. If severe manifestations occur, such as trouble breathing or loss of consciousness, emergency services must be contacted immediately.

While N-acetylcysteine (NAC) is the specific antidote for acetaminophen toxicity, management for the methocarbamol effects is symptomatic and supportive. Hospital monitoring is required, including the serial assessment of liver function tests, as maximum liver injury from acetaminophen may be delayed for 24 to 48 hours.

Therapeutic Uses of Robaxacet

What Robaxacet Treats: Main Uses and Benefits

This combination medicine is commonly used to provide symptomatic relief for acute pain associated with muscle spasm. This dual-action approach is relevant for conditions like strains, sprains, back pain, and tense neck muscles where discomfort is complicated by involuntary muscle tightness. The formulation is applied across therapeutic domains where short-term symptomatic support is needed, such as in sudden soft tissue injury. It is considered relevant in situations where symptoms become disruptive and interfere with daily functioning.

By addressing the concurring pain and localized rigidity simultaneously, the medicine plays a role in managing this symptom cluster. This supports the patient during difficult episodes by easing distress, may assist with easing discomfort, and potentially assists with maintaining functional stability during episodes of heightened symptoms.


Quick Fact: Relief for Dual Symptoms
Primary Focus Pain and involuntary skeletal muscle spasm
Context Acute, painful musculoskeletal conditions
Patient Benefit Supports managing symptom load and easing discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Robaxacet?

This section describes the official population eligibility rules for Robaxacet (Acetaminophen/Methocarbamol) as defined by government regulatory authorities.


Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Individuals with known allergy or hypersensitivity to Acetaminophen, Methocarbamol, or any other ingredient in the formulation.
  • Concurrent Medication: Patients taking other medicinal products containing Acetaminophen must not use this drug.
  • Organ Function: Patients with severe active liver disease or severe hepatic impairment.

Age-Related Eligibility and Restrictions

Age Group Eligibility Status (Regulatory Label)
Adults and Adolescents Approved for use from 12 years of age and over.
Children (Under 12) Not recommended or not indicated for use.
Geriatrics Generally acceptable, though older adults may show increased sensitivity.

Conditional Use and Special Populations

  • Liver/Kidney Disease: Conditional use; individuals with liver disease, hepatic dysfunction, or kidney disease should consult a health professional due to potential changes in drug clearance.
  • Pregnancy: Should not be used in women who are or may become pregnant, especially during early pregnancy, unless specifically advised.
  • Lactation: Use requires caution; Acetaminophen passes into breast milk, and it is unknown if Methocarbamol is excreted into human breast milk.

What should I know about interactions with other medicines?

The interaction profile for Robaxacet, a fixed-dose combination of acetaminophen and methocarbamol, is defined by pharmacodynamic reinforcement and specific restrictions documented in official regulatory labeling.

Formal Restrictions and Contraindications

The methocarbamol component is formally contraindicated for co-administration with anticholinesterase agents, such as pyridostigmine bromide, because regulatory documents state that methocarbamol may inhibit their effect. The acetaminophen component makes the product restricted for use in individuals with severe active liver disease or severe hepatic impairment due to the increased risk of exposure-related toxicity.

Central Nervous System (CNS) Interactions

Co-administration with other CNS depressants—including opioids, barbiturates, and certain psychotropic agents—results in a documented risk of additive CNS depression. This pharmacodynamic potentiation effect is a key feature of the methocarbamol profile. Alcohol consumption adds a metabolic risk due to the potential for increased hepatotoxicity with the acetaminophen component, in addition to the additive CNS depression.

Metabolic and Clearance Considerations

The profile includes a metabolic risk: co-administration with enzyme-inducing medications increases the risk of acetaminophen hepatotoxicity through enhanced formation of toxic metabolites. Methocarbamol clearance is officially documented as reduced and prolonged in patients with both hepatic and renal impairment. Furthermore, the methocarbamol component may cause color interference with laboratory screening tests for urinary 5-HIAA and VMA.

Mechanism of Action

How Robaxacet Works: Mechanism of Action

Methocarbamol and ibuprofen constitute the active components of this formulation. The overall mechanism involves the pharmacological interaction of a centrally acting agent with a peripheral anti-inflammatory agent.

Methocarbamol acts primarily on the central nervous system (CNS). Its mechanism, characteristic of a centrally acting skeletal muscle relaxant, involves generalized depression of CNS function. This action modulates polysynaptic reflex arcs without directly influencing the contractile elements of skeletal muscle fibers.

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID). Its action involves the reversible, non-selective inhibition of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition prevents the biosynthesis of prostaglandins, which function as lipid mediators in inflammatory and nociceptive signaling pathways.

This combined effect achieves a dual physiological modulation: Methocarbamol modulates the hyperactivity of skeletal muscle reflex arcs via CNS pathways, while ibuprofen restricts the synthesis of peripheral pro-inflammatory eicosanoids, leading to the suppression of both central reflex activity and peripheral inflammatory signaling.

Dosage and Administration Information

Robaxacet is formulated as an oral solid dosage form, typically a caplet or tablet, and is intended strictly for administration by the oral route. The product is a fixed-dose combination; the Extra Strength formulation, for example, combines Methocarbamol 400 mg with Acetaminophen 500 mg per caplet.

The dosing regimen specifies that adults and children aged 12 years and over should take two caplets per administration. This standard single dose is intended to be taken at a frequency of every six hours as needed. A strict maximum daily dose applies, instructing that no more than eight caplets are to be taken within a single 24-hour period.

As a critical administration constraint tied to the Acetaminophen component, total consumption of Acetaminophen from all sources should not exceed 4,000 mg per day for adults. The oral dosage form is taken without requiring special preparation and may be consumed with or without food. Consistent with its intended use for symptomatic support, the product is framed for short-term, temporary relief.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Robaxacet

Evidence for Acute Pain Associated with Muscle Spasm

The combination of acetaminophen and methocarbamol was studied for acute musculoskeletal conditions characterized by periods of heightened symptoms and involuntary muscle spasm, primarily focusing on acute low back pain. The foundational research mainly consists of Randomized Controlled Trials (RCTs) and subsequent systematic reviews applied in studies examining patient-reported experiences over short time frames. These studies were conducted during periods of increased symptom activity and typically compared the active medicine to an inactive control (placebo) or an analgesic alone.

The research so far suggests that the use of methocarbamol, alone or in combination with an analgesic, data showed patterns compared to control groups in the initial days of treatment, based on measurements of symptom change. A regulatory review examined available data for this fixed-dose combination and concluded that the evidence supported the approved indication for use in painful muscle spasms. These findings describe the patterns of symptom measurements observed in studies evaluating the muscle relaxant component over the acute treatment window.


Outcomes Measured in Clinical Trials

Research examined multiple axes related to patient experience and physical condition. The study outcomes primarily focused on patient-reported outcomes describing perceived discomfort, such as pain intensity, which was monitored in trials using standardized numeric scales. Additionally, research explored outcomes reflecting daily functioning or activity level, such as functional disability scores and physical tests monitoring spasm-related restrictions.


What is Still Uncertain About the Research Base

The certainty of the evidence remains low for some findings because evidence quality varies across studies, with many foundational trials associated with methodological quality concerns. Comparative evidence is lacking regarding whether the acetaminophen and methocarbamol combination was observed to differ when compared to taking only the analgesic component or only the muscle relaxant component. Data regarding the specific fixed-dose formulation are currently limited. These limitations mean the research provides context but not individual predictions about how any person may respond.

Key Studies & References Methocarbamol and/or paracetamol (acetaminophen) for acute non-specific low back pain: a randomized, open-label, parallel-group, multicentre study (Clinical Trial Record NCT01250269)

Frequently Asked Questions (FAQ)

Common questions about Robaxacet (FAQ)

Q: How is Robaxacet different from regular Tylenol or Acetaminophen?

A: Robaxacet is a fixed-dose combination product containing two active ingredients. It includes Acetaminophen, which is a pain reliever also found in products like Tylenol, and Methocarbamol, which is a centrally-acting skeletal muscle relaxant. Regular Acetaminophen products typically contain only the pain-relieving component, meaning Robaxacet includes the addition of a muscle relaxant.

Q: What is the main difference between Robaxacet and Robaxin?

A: Official product labeling indicates that Robaxacet contains both the muscle relaxant Methocarbamol and the pain reliever Acetaminophen. In contrast, Robaxin is a brand name often used for a medicine containing only the muscle relaxant Methocarbamol.

Q: Is Robaxacet available over-the-counter or does it require a prescription?

A: In many jurisdictions, this formulation is classified as an over-the-counter (OTC) or non-prescription medicine. However, the regulatory status may vary by country or based on the specific strength of the product.

Q: Is it safe to take Robaxacet every day for a long period?

A: Official documentation frames this product for short-term, temporary relief of acute muscle pain and spasms. Regulatory constraints indicate that using the medicine beyond its short-term intended use may increase the potential for adverse health outcomes, particularly the risk of severe liver damage associated with the Acetaminophen component.

Q: What is the typical time frame for Robaxacet to start working (onset of action)?

A: Regulatory documents indicate that the muscle relaxant component, Methocarbamol, typically begins to take effect within approximately 30 minutes after taking the oral dose. Peak concentrations in the blood are usually reached within about two hours.

Q: How long does the effect of Robaxacet generally last?

A: The effects of the Methocarbamol component generally last for about four to six hours after administration. This duration aligns with the general dosing frequency described in the product information.

Q: Can Robaxacet be used for pain that is not related to muscle spasms?

A: The official approved purpose of this fixed-dose combination product is for the simultaneous relief of pain and associated muscle spasm. The medicine's indication is specific to conditions where muscle spasm contributes to the discomfort.

Q: Are there specific signs of an allergic reaction to Robaxacet that people should know?

A: Official warnings note that a very serious allergic reaction, while rare, is possible. Signs may include a rash, itching, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing. These symptoms are described as signs of a serious reaction, which necessitates immediate medical attention.

Q: What is the interaction profile when using Robaxacet with an NSAID like Ibuprofen or Naproxen?

A: Official cautions mainly focus on risks with other CNS depressants. The concurrent use of multiple pain relievers, including a Non-Steroidal Anti-Inflammatory Drug (NSAID) like Ibuprofen, is an area where official caution is advised. Combining these types of medicines may increase the risk of overlapping side effects, such as stomach upset.

Q: Does Robaxacet interact with cannabis or marijuana products?

A: Official warnings state that the medicine may cause drowsiness and dizziness due to the Methocarbamol component’s action as a central nervous system (CNS) depressant. Official warnings indicate that the use of alcohol or marijuana (cannabis) while taking this medicine may increase the potential for drowsiness, which is associated with impaired alertness and coordination.

Q: Can Robaxacet be taken with medications for anxiety or sleep?

A: Co-administration with other central nervous system (CNS) depressants, which includes many medications used for anxiety or sleep, carries a documented risk. Official labeling warns of additive CNS depression, meaning the combined effects of drowsiness, dizziness, and impaired judgment can be intensified.

Q: What is the official status of Robaxacet concerning dependence or addiction?

A: The muscle relaxant component, Methocarbamol, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This regulatory status indicates that the product does not carry the same high potential for addiction as narcotic or controlled schedule drugs.

Q: Does Robaxacet have any known interactions with herbal supplements?

A: Official guidance describes the importance of comprehensive disclosure of all medications and supplements, including herbal products, to identify potential additive effects, particularly those related to central nervous system (CNS) depression.

Q: Can Robaxacet be used to help with tension headaches related to muscle stiffness?

A: The approved indication for Robaxacet is specifically for pain accompanied by muscle spasm. While its use is not officially indicated for tension headaches, the product's dual components—a pain reliever and a muscle relaxant—address the two primary symptoms often associated with this type of headache.

Q: Is it normal to feel a metallic taste in the mouth after taking Robaxacet?

A: Metallic taste is explicitly listed in the official documented adverse reactions associated with the Methocarbamol component of the medicine.

Q: Can Robaxacet cause stomach upset or nausea?

A: Yes, official documents list adverse reactions that may affect the Digestive System. These documented effects include symptoms such as nausea and vomiting.

Q: What are the official restrictions on activities like driving while taking Robaxacet?

A: Official warnings state that the neurological side effects (like drowsiness and dizziness) may impair the mental and/or physical abilities required for performing hazardous tasks. These warnings apply to activities that require full mental and physical ability, such as driving a motor vehicle or operating machinery.

Q: What are the differences between Robaxacet, Robax Platinum, and Robax Forte?

A: The product family involves variations in active ingredient combinations. Robaxacet combines Methocarbamol and Acetaminophen. Other variations, such as Robax Platinum, are documented to combine Methocarbamol with Ibuprofen, which is a different class of pain reliever (an NSAID) and has different safety warnings.

Q: Is Robaxacet a narcotic or a controlled substance?

A: No, the active ingredient Methocarbamol is a skeletal muscle relaxant and is not classified as a narcotic or a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Q: Does Robaxacet have an effect on a person's mood or mental clarity?

A: Adverse reactions related to the Nervous System are documented in the official labeling. These effects include the potential for symptoms like confusion and amnesia, which may affect a person's mental clarity and state.

Q: What are the reasons why Robaxacet is usually prescribed for short-term use?

A: The official protocol frames the product for temporary relief of acute muscle spasms. This short duration minimizes the risk of rare but serious adverse reactions, especially the risk of severe liver damage associated with long-term or excessive use of the Acetaminophen component.

Q: Is Robaxacet a non-steroidal anti-inflammatory drug (NSAID)?

A: No. Robaxacet (Acetaminophen/Methocarbamol) is officially classified as an analgesic and a skeletal muscle relaxant. The pain-relieving ingredient, Acetaminophen, is not an NSAID. This distinguishes it from products containing Ibuprofen or Naproxen.

Q: Can people with a seizure disorder use Robaxacet?

A: Official labeling documents that the Methocarbamol component warrants caution in patients with a known or suspected seizure disorder or epilepsy. This caution is due to reports of seizures in some contexts.

Q: Does Robaxacet interact with common over-the-counter cold and flu medicines?

A: Many common cold and flu medicines contain Acetaminophen. The primary risk is taking too much Acetaminophen from multiple products, which can lead to severe liver damage. The Methocarbamol component can also add to the sedative effect of other cold medicines.

Q: Is there a risk of rebound pain or spasms after stopping Robaxacet?

A: Official labeling does not explicitly mention a risk of rebound spasms for this product. However, for certain pain-relieving components, taking them regularly for prolonged periods may sometimes be associated with medication overuse headaches.

Q: Is Robaxacet listed as being non-addictive in official documents?

A: The active ingredients are not classified as controlled substances by regulatory bodies. This indicates they are not considered to have the same high potential for addiction as narcotic or controlled schedule drugs.

Q: Can Robaxacet affect a person's ability to concentrate?

A: Yes, neurological side effects are documented. These include confusion and the potential for impairment of mental abilities, which can affect a person's ability to concentrate while taking the medicine.

Q: Does Robaxacet contain aspirin?

A: No. Official labeling clearly lists the active ingredients in Robaxacet as Acetaminophen and Methocarbamol. It does not contain Aspirin.

Q: Can Robaxacet cause constipation or diarrhea?

A: Official labeling lists GI upset as a possible adverse effect related to the digestive system. While specific terms like 'constipation' or 'diarrhea' are not consistently listed for this combination product, digestive side effects are documented.

Q: How does the action of Robaxacet differ from applying a topical heat rub?

A: Robaxacet is a medicine that works internally. Acetaminophen acts to relieve pain, and Methocarbamol works via the central nervous system to relax muscle spasms throughout the body. A topical heat rub is applied externally and acts locally on the skin to provide surface heat sensation.

Q: Does taking Robaxacet affect the results of any specific medical lab tests?

A: Yes. Official documentation warns that the Methocarbamol component may cause color interference with certain laboratory screening tests for urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

How should Robaxacet be stored and disposed of?

Storage and Protection Requirements

This medication must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C [DailyMed]. To protect the integrity of the oral solid dosage form, the product must be dispensed and kept in a tight container. Consistent with all regulatory standards, the medicine must be kept out of the reach of children and pets at all times.

Official Disposal Instructions

When disposing of unused or expired product, the primary method recommended by regulatory agencies is to utilize drug take-back programs or authorized collection sites [FDA]. If these options are not available, the medication can be safely discarded in household trash by first mixing the tablets with an undesirable substance, such as used coffee grounds or cat litter. The mixture must then be placed in a sealed container before final disposal to prevent access and accidental ingestion. The product is not listed as a medication that should be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Robaxacet found in:

A-Z Index: